Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Conagra Brands Inc (CAG) vs Novo Nordisk A/S (NVO) Price & Performance

Conagra Brands IncTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Conagra Brands Inc vs Novo Nordisk A/S — how do they compare? Conagra Brands Inc trades at $14.85 (market cap $7.14B), while Novo Nordisk A/S trades at $46.1 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 29.1× Conagra Brands Inc's market cap, and Conagra Brands Inc pays the higher dividend (8.2%). Which is the better fit depends on your goals.

CAGNVO
Market Cap
$7.14B$207.85B
Sector
Consumer StaplesHealth
52-Week High
$20.02$63.98
52-Week Low
$12.58$35.29
Enterprise Value
$14.20B$222.55B
Dividend Yield
8.2%3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Conagra Brands Inc

Conagra Brands (CAG) trades at $14.78, down 2.18% today, with a bearish technical signal and neutral oscillators. The company reported a net income margin of -16.99% for 2026, with revenue declining to $11.3B, while 2025 showed stronger profitability. Recent corporate actions include a dividend cut to $0.18 and leadership changes under CEO John Brase, aiming to streamline operations and reduce debt.

The outlook is mixed: low valuation metrics (P/E 10.06, P/S 0.63) offer downside support, but weak growth and margin pressures pose risks. Analyst consensus is cautious with a $13.67 price target, and institutional sentiment is divided amid ongoing turnaround efforts. Key risks include consumer pushback on pricing and execution challenges under new management.

Novo Nordisk A/S

NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.

The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Conagra Brands Inc

Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.

Read more on CAG

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO